Q-omics provides the consensus-scored HNRNPA3P15 profile across patient tissues and cancer cell-line models. HNRNPA3P15 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, HNRNPA3P15 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, HNRNPA3P15 RNA expression shows 16,295 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, BRCA, and LSCC as cancer lineages where HNRNPA3P15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA3P15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA3P15 survival associations across molecular data types. HNRNPA3P15 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA3P15 RNA expression–survival associations across cancer types. High HNRNPA3P15 expression shows unfavorable associations in CHOL, but favorable associations in UCS, LGG, READ, OV and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify UCS as the clearest survival context for HNRNPA3P15 RNA expression.
This table summarizes HNRNPA3P15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA3P15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA3P15 shows higher tumor expression in BRCA and BLCA. The BRCA box plot shows higher HNRNPA3P15 RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p = .022).
This table shows molecular features associated with HNRNPA3P15 in patient tissues and cancer cell lines. In patient samples, HNRNPA3P15 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
